SANDOZ GROUP AG

Canadian regulators approve Sandoz’s generic semaglutide, while a new biosimilar deal with mAbxience expands affordable GLP‑1 and hemophilia treatment access worldwide.

Explore how Sandoz’s Bio100 plan and new Ljubljana manufacturing hub aim to dominate the affordable biosimilar market in this “golden decade.”

Strong first‑half 2026 results for Sandoz Group AG show biosimilar growth driving revenue up 10% and solid margins, while a $450M U.S. settlement clears legal hurdles for continued earnings momentum.

Discover how Sandoz’s $350 M acquisition of Just‑Evotec Biologics boosts its biosimilar manufacturing power and positions the company to tap a $300 bn market.

Explore how Sandoz Group AG’s launch of Afqlir and its sharp stock volatility reflect a high‑growth pharma strategy, yet raise caution for investors.

Sandoz Group AG has announced a potential acquisition of Just-Evotec Biologics, a biologics development and manufacturing facility in France, in a deal valued at approximately $300 million.